Figure 2.

Progression‐free survival (PFS) (A) and overall survival (OS) (B) stratified by above/below median plasma concentrations at baseline of biomarkers with adjusted P < .05 for PFS or OS. These biomarkers were extracellular newly identified receptor for advanced glycation end‐products binding protein (EN‐RAGE), insulin‐like growth factor‐binding protein 1 (IGFBP‐1), interleukin‐8 (IL‐8), kallikrein 5, pulmonary surfactant‐associated protein D (SP‐D), tenascin‐C (TN‐C), tissue inhibitor of metalloproteinases 1 (TIMP‐1), and tumor necrosis factor receptor 2 (TNFR2). ***P < .001; *P < .05; NS, not statistically significant